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Impact of a 4-Week Home-Based Exercise Program on the Functional Capacity of Advanced 




 Research has demonstrated that a physically active lifestyle can counter some of the cardio-
respiratory and musculoskeletal losses associated with cancer. Still, exercise guidelines for 
advanced cancer patients are unspecific, and exercise prescription can be complicated, due to a 
multitude of factors that may influence the degree of physiological and functional decline from 
patient to patient. In the present study, twenty-one supportive care patients with stage III or IV 
cancers were prescribed a 4-week exercise intervention, in conjunction to standard care. The 
program included 12 unsupervised resistance training and walking sessions, and participants 
were assessed pre and post exercise intervention. The primary aim of this study is to examine 
pre-post exercise program changes in function, strength, body composition, energy expenditure, 
and health-related quality of life (HRQOL). Functional tests, including the 6-minute-walk-test 
(6MWT) were used to assess performance. Body composition was assessed using dual-energy x-
ray absorptiometry (DXA) and accelerometers were used to assess energy expenditure and step-
count before and after exercise intervention. The Edmonton Symptom Assessment System 
(ESAS) and the abridged Patient-Generated Subjective Global Assessment (aPG-SGA) 
questionnaires were used to examine symptom profile and health related quality of life 
(HRQOL). We hypothesized improvements in functional scores and increased daily energy 
expenditures post-exercise as compared to baseline.  The secondary aim of the study is to assess 
its feasibility in the given population. Feasibility was evaluated based on: i) recruitment rate, ii) 
retention rates, iii) test performance, iv) exercise program tolerability, and v) adherence to 
prescription. Paired t-tests were used to assess pre-post intervention differences. Findings 
indicate statistical and clinical significant improvement in 6MWT distance. Pre-post reports of 
HRQOL were maintained with significant decrease in pain. Upper and lower body strength 
significantly improved over the 4 weeks. Daily energy expenditure and daily step-count also 
showed meaningful increase post-exercise intervention. Our findings suggest that, the proposed 
exercise prescription encourages a more active lifestyle and can improve functionality of 
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Cancer and Projected Statistics in Canada 
Cancer is the second leading cause of death worldwide, accounting for every 1 in 6 
deaths globally in 2018 (WHO, 2018). In Canada, cancer is the primary cause of death for 1 in 4 
Canadians (Canadian Cancer Statistics, 2018). Projected statistics report that the four most 
commonly diagnosed cancers will remain the same, and include: lung, breast, colorectal, and 
prostate cancers (WHO, 2018). Together, these four major cancers will encompass half of newly 
diagnosed cancers by 2030, and will primarily affect the senior population (Canadian Cancer 
Statistics, 2018). Closely followed by colorectal cancers, prostate cancer will be the most 
commonly diagnosed cancer as Canadian men age, with a survival rate of five years. Fortunately, 
cancer survival rates have generally improved in the last few decades, and continue to improve 
due to new advancements in technologies, screening processes, and treatments. Improvements in 
cancer management are also reflected in that the incidence rate for all cancers combined is 
expected to remain steady in the coming years (Canadian Cancer Statistics, 2018). 
Nevertheless, according to recent statistic publications by the Canadian Cancer Society 
Statistics Report (2018), 1 in 2 Canadians will be diagnosed with cancer at some point in their 
lifetime, and only half are expected to survive (See Appendix A). Moreover, the total number of 
Canadians diagnosed with cancer is on the rise. The reported long-term projections, estimate that 
number of cancers diagnosed in 2030 will be increased by 80% as compared to 2005 (Canadian 
Cancer Statistics, 2018).  This dramatic increase is partly due to the fact that Canadians are 
growing older as a population. In fact, by the year 2030, the number of adults aged 65 and over 
will have doubled, jumping from a ratio of 1 in 8 to 1 in 4.  Canada’s population is also 
increasing in number, and is expected to welcome another 10 million people by 2030 (Canadian 
Cancer Statistics, 2018). These increases in population size and age will challenge Canada’s 
health care system, and the surge in cancer cases may push it to capacity.  In consequence, there 
is urgent need for improved, feasible, and effective cancer management plans.  
 






Introduction to Cancer & Pathophysiology Overview 
Cancer is an umbrella term used to describe a group of related diseases. In all cancers, 
some of the body’s cells will start to divide abnormally without stopping (NCI, 2015). Normally, 
cells follow an orderly cycle of life and death. New cells mature, and when they become old, 
damaged, or abnormal, they die, and new ones replace them. Contrastingly, in the case of 
cancers, when abnormal or dysplastic cells develop, they continue to survive and multiply in an 
uncontrolled fashion called hyperplasia (NCI, 2015). Cancer cells are different from normal 
cells, because they lack specific function and can continue to grow where they are not needed, 
ignoring normal cues for apoptosis. These extra cells continue to divide and proliferate, and may 
collect to form a cancerous tumor (NCI, 2015).  
Essentially, tumors are classified in one of two categories: benign or malignant. Some 
tumors are considered benign, which means that are incapable of spreading and typically will not 
cause harm, unless they grow large, and compress other important structures like vital organs. 
Benign tumors can be removed surgically and usually do not grow back. In contrast, cancerous 
tumors are considered malignant, meaning that they are capable of spreading and invading other 
tissues, and even if they are surgically removed, run the risk of growing back (NCI, 2015). With 
cancerous tumors, metastasis of cancer cells is possible through the blood or lymphatic system to 
reach other areas in the body, away from the original tumor site. Furthermore, cancerous tumors 
can suppress the immune system, and can control certain immune cells to protect the tumor from 
immune system attack. Similarly, cancer cells may relinquish control of normal cells to feed and 
supply the tumor. For example, cancer cells will use normal cells to build blood vessels for the 
tumor, so it can absorb nutrients and oxygen and expel waste like healthy body tissues do (NCI, 
2015).   
 
Cancer Classification  
Classifications of both benign and malignant tumors are based on the type of cell they 
arise from. The majority of cancers will fall into one of the following classes: carcinomas, 
sarcomas, leukemia, lymphomas, myelomas, or central nervous system cancers (Cooper, 2000). 
Carcinomas, which represent 90% of human cancers, originate in epithelial cells, which line the 
body’s inner organs, cavities and outer skin. Appearing more rarely, sarcomas will originate in 





lymphomas, and myelomas will originate in the bone marrow, the lymphatic system, and the 
immune system, respectively. Lastly, cancers originating in the brain or spinal cord are known as 
central nervous system cancers (Cancer Research UK, 2017). Cancers are also named based on 
the body part they originate in, like breast or lung carcinomas, for example. Even when cancer 
metastasizes, it is named after the primary cancer site (Cooper, 2000). For instance, if breast 
cancer metastasized to the lung, it is called metastatic breast cancer to the lung and not lung 
cancer (Canadian Cancer Society, 2018). 
 
Cancer Staging 
A pathology test is usually necessary to identify and grade a cancer. This involves a 
biopsy of the tumor that is then examined under the microscope for presence of malignancy, type 
and stage of cancer (Quebec Cancer Foundation, 2017). Typically, cancers are staged using the 
“T-N-M” grading system (Canadian Cancer Society, 2018) (See Appendix B). This globally 
recognized grading system is broken down into 3 key criteria, where ‘T’ is for tumor size, ‘N’ is 
for number of lymphatic nodes affected and ‘M’ is for metastasis. Tumor size refers to the 
primary cancer tumor and it’s invasion to local tissues if any. To stage the size of the tumor, ‘T’ 
is followed by a number from 1 (smallest) to 4 (largest). Similarly, the number of nodes affected 
is denoted as ‘N’ followed by a number from 0 (least extension) to 3 (most extension). In turn, 
‘M’ will be followed by either 0 (absent) or 1 (present), indicating presence or absence of 
metastasis. In some cases, lowercase letters are used to further specify the degree of metastasis 
(Canadian Cancer Society, 2018). Other times, cancer may be difficult to stage, for example, if 
cancer is advanced and history of primary tumor is unknown. In the case of brain cancers, 
grading will be different, because brain cancer will not metastasize beyond the central nervous 
system (Quebec Cancer Foundation, 2017). 
 
Epidemiology and Risk Factors 
Pathophysiological mechanisms for cancer are attributed to various causes. Established 
causes include genetic material being mutated by errors in replication or repair processes, 
exposure to various environmental factors and carcinogens, or through certain viruses (e.g. 
Epstein-Barr virus, hepatitis B and C, human papillomavirus) (Cooper, 2000 ; Arem et al. 2018). 





tumor-suppressor genes, and DNA repair genes (NCI, 2015). Changes in proto-oncogenes, which 
are responsible for normal cell division and growth, solicit development of oncogenes, which 
enable cells to live passed their expiration date and multiply uncontrollably (NCI, 2015). 
Similarly, tumor-suppressor genes also control proper growth and division of cells. Therefore, 
alterations in tumor-suppressor genes will also enable uncontrolled growth and division of cells. 
Lastly, DNA repair genes, which are responsible for mending damaged cells, may present with 
mutations. In consequence, mutated cells in DNA repair genes can transfer mutations onto other 
genes, and together these mutations can create cancerous cells (NCI, 2015). Molecular research 
finds that certain mutations correlate with certain cancers. Thus, cancers are also commonly 
characterized by the gene alterations that seem to be driving them regardless of where they 
appear in the body or how cancer cells appear under the microscope (NCI, 2015). 
Besides non-modifiable genetic alterations, there exist many modifiable risk factors to 
cancers that we can control through improved lifestyles. According to a recent review by Arem 
and Loftfield (2018), up to half of incident cancers appear to be caused by modifiable risk 
factors. Lifestyle choices like eliminating tobacco use, using sunscreen, moderating alcohol 
consumption, and being physically active, may significantly reduce risk of cancer (Arem et al. 
2018).  
 
Supportive Care Treatments for Advanced Cancers 
For advanced cancer patients, aggressive chemo-radiotherapy treatments (CRT) are most 
often required for a chance to survival. Chemo-radiotherapy treatments are an integral part of 
cancer management and are prescribed to cancer patients in order to kill cancer cells, downsize 
cancerous tumors, improve operability and decrease likeliness of cancer recurrence (Andre et al., 
2009; Vicini et al., 2002; Burris, 1997). Despite its effectiveness against cancer cells, CRT has a 
very high toxicity profile for the whole body, and is deleterious for many non-cancerous, healthy 
cells (West et al., 2014; Cancer Research UK, 2005).  Consequently, advanced cancer patients 
undergoing CRT are often impacted by decreases in muscle tone and cardio-respiratory fitness, 
as well as, significant increases in fatigue level and weakness (West et al., 2014; Gilliam et al., 
2011; Van Norren et al., 2009; Carvalho et al., 2009; Chen et al., 2007). Sometimes, cancer 
treatments may also inflict cognitive deficiencies like declines in attention, memory and 





removal of tumor) in addition to receiving CRT treatments, physical and functional decline are 
always expected, and even more so, for patients who are deconditioned before surgery. 
Deconditioned patients will also have an increased risk of surgical complications (Christensen, 
1993). 
 
Cancer & Treatment-Related Declines 
Fatigue is by far, the most debilitating symptom reported by cancer patients. Fatigue is 
also the number one anticipated side-effect even before patients start receiving treatments, 
according to the large scale Rochester Cancer Center Community Clinical Oncology Program 
study, which included 938 patients (Hoffman et al., 2004). Even without treatments, cancer-
related fatigue is widely reported by patients upon cancer diagnosis and persists post-treatment 
for many survivors (Hoffman et al., 2007).  Cancer related fatigue is not the same as ‘regular’ 
fatigue or drowsiness experienced by healthy individuals, as it is not relieved by rest or sleep 
(Hoffman et al., 2007). Unsurprisingly, exposing the already chronically fatigued body to 
aggressive CRT treatments only amplifies the degree of fatigue experienced by supportive care 
patients. Research indicates that up to 80% of patients undergoing chemotherapy and up to 90% 
of patients undergoing radiation therapy experience fatigue (Hoffman et al., 2007; Curran et al., 
2004; Schwartz et al., 2000).  
The onset of fatigue in cancer patients contributes to decreased physical and functional 
capacities. The mechanism of physical fitness decline due to CRT is not fully understood. 
However, it is known that oxidative damage from chemotherapy can cause an up-regulation of 
ubiquitin-ligase (an enzyme that signals the degradation of proteins), an increase mitochondrial 
death, and important losses in muscle mass (Buttke et al., 1994). Other known mechanisms 
include interactions with oxygen to produce reactive oxygen species (ROS) (Chen et al., 2007), 
while others include decreased antioxidant levels. In sum, although mechanisms remain obscure, 
many chemotherapeutic agents affect cardio-respiratory and microcirculatory function, as well 
as, mitochondrial and cellular metabolism. Consequently, these mechanisms lead to increased 
fatigue, especially in advanced cancer patients, and even more so in patients with cachexia 
(muscle wasting syndrome), who can lose up to 75% of their skeletal muscle mass (Preston et al., 
1987). Such losses in muscle mass result in increased fatigue, decreased quality of life, and 





Radiation therapy has also been associated to tissue fibrosis (Renzi et al., 1992) and 
arteriosclerosis (Rubin et al., 1992). When chemotherapy and radiotherapy treatments are 
combined, the negative effects on cardiovascular and muscular systems are amplified (Bezwada 
et al., 1998), sometimes resulting in left ventricular function impairments, abnormal pressure and 
volume relationships and decreased ejection fraction (d'Avella et al., 1998). Depending on the 
specific type of anti-cancer treatment, side effects may including anemia, appetite loss, nausea, 
hair loss, diarrhoea, hand-foot syndrome, cardiotoxicity and haematological toxicity (Rubin et 
al., 1992 ; d'Avella et al., 1998). Moreover, a study by Woo et al. (1998) showed that cancer 
survivors having undergone both chemotherapy and radiotherapy experienced higher levels of 
fatigue and showed lower functional capacity scores than their counterparts who had received 
one of the treatments exclusively.  
Recent studies have quantified the impact of CRT on cardio-respiratory fitness in cancer 
patients. Findings from cardiopulmonary exercise testing (CPET) indicate that oxygen uptakes 
(VO2) at ventilatory threshold and peak exercise (VO2peak) were significantly reduced (Fresard et 
al., 2013; Jack et al., 2016; Sinclair et al., 2014; Yeh et al., 2004). In fact, it has been suggested 
that 12 weeks of chemotherapy is equivalent to an entire decade of physical decline in terms of 
cardio-respiratory fitness (Lakoski et al., 2012). The decline in red blood cells, hemoglobin, and 
overall decline in cardio-respiratory fitness attributed by chemotherapy treatments, in 
conjunction with tissue fibrosis (often seen in lungs) and, at times, cardiac abnormalities 
attributed by radiation therapy, increases risks of cardiovascular disease mortality and mortality 
in general (Yeh et al., 2004, Darby et al., 2003; Huddart et al., 2003) . Naturally, factoring in 
sedentary behavior -which is often seen in cancer patients-, adds to the heavy burden on the 
cardio-respiratory system (Lakoski et al., 2012). Decreases in physical activity (PA) due cancer-
related fatigue, depression or lack of motivation may result in reduced muscle and bone mass, 
decreased strength, endurance, heightened symptoms and increased pain. Consequently, patients 
experience decreases in functionality as they struggle to execute activities of daily living, 
increase their dependency and experience poorer HRQOL (Vogelzang et al., 1997). 
Increased physical decline is also a reality for patients undergoing curative surgery. 
Firstly, decline in cardio-respiratory fitness  associated to pre-operative CRT treatments increase 
risks of surgical complications (West et al., 2015). Close to one-third of patients undergoing 





et al., 2008) including wound infection, gastrointestinal infection, and motility complications like 
ileum and bowel obstruction (Tevis et al., 2016). Even in the absence of complications, major 
surgeries are associated to a 40% reduction in physiologic and functional capacities (Christensen 
et al., 1993). 
The table below, published by Kleckner et al. (2018), summarizes the most prevalent 
toxicities attributed to cancer and its treatments. Toxicities listed in this abridged table appear in 
order of high priority, identified by the National Community Oncology Research Program (NCI-
NCORP, 2015). 
 
Table 1: High priority toxicities from cancer and its treatments 
Toxicity Definition Prevalence 
Fatigue Distressing, persistent, subjective sense of physical, 
emotional, and/or cognitive tiredness or exhaustion 
related to cancer or cancer treatment that is not 
proportional to recent physical activity and interferes 
with usual functioning (Berger et al., 2010) 
• Approximately 80–100% of patients with 
cancer (Stone et al. 2000) 
• Approximately 25–33% of cancer 
survivors up to 10 years after diagnosis 
(Carson et al., 2009; Bower et al., 2012) 
Cardiotoxicity Damage to the heart, leading to chest pain, shortness of 
breath, heart attack, and heart failure. Cardiotoxicities 
include cardiomyopathy, myocarditis, pericarditis, acute 
coronary syndromes, and congestive heart failure 
(National Comprehensive Cancer Network, 2017) 
• Approximately 27% of patients receiving 
the HER2-inhibitor trastuzumab  
• Approximately 20–50% of patients 
receiving inhibitors of VEGFA  
• Approximately 7% of patients receiving 
tyrosine kinase inhibitors  
• Risk is elevated from chest radiotherapy 
(Moslehi, 2016) 
Pain An unpleasant sensory and emotional experience 
associated with actual or potential tissue damage (IASP, 
2004) 
 Approximately 59% of patients with cancer 
(Chang et al., 2000) 
Cognitive 
impairment 
Impaired learning, memory, attention, and speed of 
information processing (Dietrich et al., 2008) 
• Up to 75% of patients with cancer and 
cancer survivors (Janelsins et al., 2011) 
Neurotoxicity Damage to nerve cells in the brain, spinal cord, or 
periphery (Dietrich et al., 2008) 
Peripheral neuropathy can cause pain, numbness, 
tingling, cramping, motor problems, balance 
impairment, and sexual dysfunction (Postma et al., 2005) 
• Up to 68% of patients 1 month after 
completing neurotoxic chemotherapy  
• Up to 30% of patients 6 months after 
completion of neurotoxic chemotherapy 
(Seretny et al., 2004) 
This list only includes highest priority toxicities determined by the National Cancer Institute (NCI) Community Oncology 
Research Program (NCORP) Symptom Management Committee.HER2 = human epidermal growth factor receptor 2; VEGFA = 







Cachexia, which is characterized by generalized weight loss and muscle wasting, often 
occurs in consequence of advanced cancers and other chronic disorders. Cancer cachexia is most 
prevalent in gastrointestinal, pancreatic, lung and colorectal cancers (Dodson et al., 2011). 
According to a consensus conference for physicians, which took place in Washington in 2008, 
the clinical definition of cachexia is as follows:  
 
“Cachexia is a complex metabolic syndrome associated with underlying illness and 
characterized by loss of muscle with or without loss of fat mass. The prominent clinical 
feature of cachexia is weight loss in adults. Anorexia, inflammation, insulin resistance and 
increased muscle protein breakdown are frequently associated with cachexia. Cachexia is 
distinct from starvation, age-related loss of muscle mass, primary depression, 
malabsorption and hyperthyroidism and is associated with increased morbidity.”  
(Evans et al., 2008) 
 
Due to the heterogeneous features of cancer cachexia, its identification poses challenge to 
clinical practitioners, and only recently, has there been development of a cancer-cachexia 
classification system using specific clinical criteria (Vigano et al., 2016). The defined 
classification system includes four different cachexia stages: non-cachexia, pre-cachexia, 
cachexia, and refractory cachexia. Each stage is defined according to the following five criteria: 
abnormal biochemistry (A), decreased food intake (B), moderate weight loss (C), significant 
weight loss (D), and decreased activities and functioning (G) (see Appendix C). 
 
The Role of Exercise  
Recent findings demonstrate that patients who adopt a physically active lifestyle while 
receiving treatments are able to counter some of the cardio-respiratory losses attributed by CRT. 
Consequently, physically active cancer patients report less depression and a better HRQOL 
(Mishra et al., 2012; Burke et al., 2013; Cheville et al., 2013; Furmaniak et al., 2016; Brunet et 





For patients undergoing surgery, ‘prehabilitation’, or pre-operative exercise intervention, 
is emerging in the oncology field as a relevant tactic to increase pre-operative functional reserve 
(Le Roy et al., 2016). Recent research stipulates, that better results in pre-operative VO2peak, 6-
minute walk, and anaerobic threshold tests, predict reduced risk of post-surgical morbidities 
(Hennis et al., 2011). Prehabilitation exercise programs can also prevent fatigue and physical 
declines associated to pre-operative CRT treatments (Le Roy et al., 2016). 
For patients undergoing CRT treatments, some exercise programs have successfully 
reversed the deconditioning process attributed by anti-cancer treatments (Courneya et al. 2007; 
Segal et al., 2009). For example, Courneya et al. (2007) used aerobic training to halt VO2peak 
decline in breast cancer patients receiving chemotherapy.  Similarly, Segal et al. (2009) 
counteracted cardio-respiratory declines using an aerobic and resistance exercise program in 
prostate cancer patients receiving radiotherapy. Remarkably, one breast cancer study was 
successful in achieving an overall increase in cardio-respiratory fitness (11.8% increase over 
intervention period) using aerobic interval training (Jones et al., 2011).  Strength and endurance 
training programs also help reduce cancer-related fatigue and are recommended to all patients 
experiencing fatigue (Dimeo et al., 2001; Schmitz et al., 2010). Moreover, PA has been 
associated with reduced occurrence and recurrence of several cancers (Irwin et al., 2008; Holmes 
et al., 2005; Holick et al., 2008). Namely, study results suggest that post-diagnosis PA can 
reduce breast cancer deaths by 34 %, all-cause mortality by 41 % and disease recurrence by 24 % 
(Ibrahim et al., 2011). In colon cancers, moderate levels of PA have also been associated with a 
lower risk of death in (Meyerhardt et al, 2006). 
 
Exercise in Cancer Rehabilitation  
Physical activity during cancer treatment has delivered some promising results. 
Numerous studies have illustrated exercise can correct and prevent some of the compromising 
effects of cancer treatments like fatigue and decreased functionality. The following tables 









Table 2: Literature Review of Exercise Interventions Studies in Supportive Cancer Patients  
 
Researchers (Year) Participant 
characteristics 
Exercise type Length and 
Frequency 
Intensity Outcome measure 
Results 
Winningham et al. 
(1988) & (1989) 
Female,  
45-48 yrs old 
Breast Cancer, stage II 
(n=42 in1988)  
(n=24 in 1989) 




60-80% HRmax ↔ Arm circumference 
↑Lean body mass 
↓nausea, ↓body fat 
  
 




Breast Cancer, stage II 
(n=45) 
43-46 yrs old 
CV; IT cycling 10 weeks 
3x/week 
 
60-85% HRmax ↓Skinfold sites 
↑42% VO2peak 
Schwartz et al. 
(2000) & (2001) 
Female 
Breast Cancer 
(n=27 in 2000) 






35 mins/session  
 
2001: 3 chemo 












2001:↑15% 12MWT  
Segal et al. (2001) Female  
Breast Cancer 
Stages I and II 
(n=123) 
















larger change in 
function when 
compared to control 
than supervised. 






Resistance 12 weeks 
3x/week 
2 sets, 12 reps 
60-70% 1-RM 
 
↑42% UB strength 
↑36% LB strength 
↓5%  resting SBP 
↑HRQOL 
Kolden et al. 
(2002) 
Female 
Breast Cancer stage I 
and II 










Unspecified ↑34.5% UB strength 
↑37% LB strength 
↑15.4% VO2max 
↑11%  flexibility 
Adamsen et al. 
(2003) 
Male, Female 
Leukemia, breast, colon, 












3 sets, 5-8 reps 
 
60-100% HRmax 
85-95%  1-RM 
 
↑32.5%  WB strength 






Table 3: Literature review of exercise intervention studies in cancer patients taking place over 4 





Exercise type Length and 
Frequency 
Intensity Outcome measure 
Results 
Dimeo et al. 
(2008) 
Male and Female 
Cancer patients 















30 min on treadmill 
walking 
↑physical performance 
↓ mental and physical 
fatigue 
↔ depression, anxiety or 
cognitive fatigue 
Li et al.    (2012) 
 

















assessed 4 and 8 
weeks post 
surgery) 
30 mins walking 
moderate intensity 
and 30mins of 
resistance training 
↑walking capacity and 
recovery speed of 
experimental group 





Gillis et al.  
(2014) 

























5-min warm-up, 20 
min of aerobic 
exercise (starting 
at 40%HRR), 20 min 
of resistance training 
(8 exercises for major 
muscle at  




Meaningful changes in 
postoperative functional 
exercise capacity achieved 
with 4 week 
prehabilitation 
 













warm up (10 min), 
strength (10 min), 
aerobic (40 min), 
core stability (10 
min), cool down (10 
min) 




Dunne et al.  
(2016) 










5 min warm-up & 




↑preoperative VO2 at 
anaerobic threshold and 




CV=cardiovascular, CPET= cardiopulmonary exercise test, HRQOL= health related quality of life, 6MWT=6minute 
walk test, IT=interval training, UB, LB, WB= upper/lower/whole body. 





Discussion of literary review 
 
In general, findings indicate positive physical and psychological outcomes through 
exercise intervention. As seen in Table 2, many of the earlier exercise intervention studies have 
focused on early stage breast cancer patients (Winingham et al., 1988 & 1989 ; Macvicar et al., 
1989; Schwartz et al., 2000 & 2001), but more recent studies have included a wider array of 
cancer patients (Adamsen et al., 2003; Dimeo et al., 2008). Also, many of the earlier studies 
focused on aerobic training (Winingham et al., 1988 & 1989; Macvicar et al., 1989; Schwartz et 
al., 2000 & 2001) rather than resistance training or mixed programs. In contrast, more recent 
works presented in Tables 2 and 3, include mixed training programs incorporating aerobic, 
resistance and flexibility into exercise sessions (Gillos et al., 2014; Do et al., 2015; Dimeo et al., 
2008). Exercise program length, frequency, and, intensity values also varied significantly from 
study to study, making it difficult to pinpoint the best guidelines for exercise prescription in this 
population. A closer look reveals that most exercise interventions prescribed ‘moderate’ intensity 
exercise or created personalized goals for patients according to their baseline fitness assessments. 
However, there is a general lack of instruction regarding specific exercises used for resistance 
training intervention. Listed in Table 3 are studies that include shorter exercise intervention of 4 
weeks or less. Interestingly, though these interventions are quite short, they still produced 
significant improvements in functional and cognitive measures. However, there is still a lack of 
studies examining advanced cancers in supportive care, and shorter interventions mainly focus 
on preparation and response to surgery (Gillis et al., 2014; Li et al., 2012). Moreover, there have 
been no short-term studies (≤4 weeks) examining changes in body composition, strength, and EE 
before and after exercise for advanced supportive care patients. Also, the use of objective tools, 
such as, DXA for tracking changes in body composition (reference standard), just as, the use of 
accelerometers for tracking PA, have not been reported in short-term, supported care studies to 
date. Thus, further research is required to investigate changes attributed by short-term exercise 
interventions. Moreover, screening for cancer cachexia is not something that is discussed by any 
of the aforementioned studies, and its importance will be addressed in the next chapter. Overall, 
more research is required on the aforementioned fronts, and the following study attempts to 






Project overview  
Standard care for advanced cancer patients consists of the administration of 
pharmaceutical treatments, and regular follow-ups by various health care professionals including 
physicians, physiotherapists, and nutritionists. Despite findings that exercise programs offer 
significant benefits to advanced cancer patients, professional kinesiologist consultations are not 
yet offered to patients as part of standard care services. Moreover, exercise guidelines for 
advanced cancer populations are still very unspecific and exercise prescription can be 
challenging, due to a multitude of factors that may influence the degree of physiological and 
functional decline from patient to patient. Few studies have examined both functional 
performance and physiological changes after brief (4-week) exercise intervention, along with, 
changes in daily energy expenditure in a group of patients. The objective of this study is to assess 
the feasibility of a 4-week, home-based exercise program prescribed to patients receiving 
supportive care at McGill University Health Center’s (MUHC) cancer clinic. More specifically, 
inclusion criteria qualified patients with stage 3 or 4 cancers, receiving anti-cancer treatments, 
and without cachexia according to the criteria defined in Appendix C (Vigano et al., 2016). All 
study participants (N=21) received consultation with a kinesiologist and were prescribed exercise 
intervention for 4 weeks in addition to their standard care. To measure changes in performance, 
the study called for a pre-post intervention design with the 6MWT as primary outcome measure. 
Tests included in the Short Physical Performance Battery were secondary measures in assessing 
performance. Body composition was assessed using dual-energy x-ray absorptiometry (DXA) 
and accelerometers were used to assess energy expenditure and step-count before and after 
exercise intervention. Gains in strength were quantified in regards to progression in Theraband™ 
resistance. We hypothesized improvements in all functional scores, overall body strength, and 
increased daily energy expenditures post-exercise as compared to baseline. Paired t-tests were 
used to assess pre-post exercise differences. Feasibility was evaluated based on: i) recruitment  
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Introduction: Few studies have examined both functional performance and physiological 
changes after brief (4-week) exercise intervention, along with, objective changes in daily energy 
expenditure in a group of patients. The current study investigates the impact of a 4-week, 
unsupervised, exercise program in stage 3 and 4 cancer patients with a variety of malignancies 
undergoing supportive care. The primary aim was is to examine pre-post interventional changes 
in function, body composition, energy expenditure, and health-related quality of life (HRQOL). 
The secondary aim of this study was to assess its feasibility. Feasibility was evaluated based on: 
i) recruitment rate, ii) retention rates, iii) test performance, iv) exercise program tolerability and 
v) adherence.  
Methods: All participants (N=21) took part in a prescribed home-based exercise program, which 
included 12 unsupervised training sessions over a 4-week period. Study design compared pre-
post intervention outcome measures. Each training session included self-paced walking, 
Theraband™ resistance exercises of the upper and lower body, combined with balance and 
flexibility exercises. Participants were asked to keep record of each session in a provided 
logbook. Our primary outcome measure for functional performance was the 6-minute-walk test. 
In addition to traditional functional tests, body composition was assessed using reference 
standard, DXA, and accelerometers were used to objectively assess energy expenditure and step-
count before and after exercise intervention. Lastly, the Edmonton Symptom Assessment System 
(ESAS) and the abridged Patient-Generated Subjective Global Assessment (aPG-SGA) 
questionnaires were used to examine symptom profile and HRQOL. We compared all pre-post 
exercise group means using paired t-tests.  
Results: Results of primary outcome measure showed statistical and clinical improvement in the 
6MWTD of +44.2 ± 38.0 (𝑥 � ±  SD) between pre and post-intervention assessments. Total SPPB 
scores were also significantly improved post intervention, primarily due to significant 
improvement in sit-to-stand time (p=0.025). Lean body mass also showed a trending increase 
(p=0.066), while fat mass and bone mineral compositions were maintained. Significant increases 
in end intervention energy expenditures and step count (p=0.01 for both) showed positive 
behaviour modification and increased PA. There was an improvement in overall body strength as 
evidenced by the significant increase in elastic resistance in the chest press, seated row, and 





throughout the study. To verify feasibility we calculated a retention rate of 75%, recruitment rate 
of 29%, and adherence rate of 85%. Because these figures are comparable to those of other 
cancer-exercise studies, a future randomized control trial is feasible. 
Conclusion: Our findings imply that the current exercise prescription is beneficial to, and well 
tolerated by, advanced cancer patients undergoing supportive care. Comparisons between pre-
post intervention outcome measures revealed promising improvements in functionality, walking 
capacity, overall muscle strength, and increased PA.  
 
Keywords: Cancer rehabilitation, exercise, 6MWT, resistance training, energy expenditure, 








Chemo-radiotherapy treatments (CRT) are an integral part of cancer management and are 
prescribed to cancer patients in order to kill cancer cells, downsize cancerous tumors, improve 
operability and decrease likeliness of cancer recurrence (Andre et al., 2009; Vicini et al., 2002; 
Burris, 1997). Despite its effectiveness against cancer cells, CRT has a very high toxicity profile 
for the whole body, and is also deleterious to healthy cells (West et al., 2014; Cancer Research 
UK, 2005).  Consequently, patients undergoing CRT are often impacted by decreases in muscle 
mass and cardio-respiratory fitness, as well as, significant increases in fatigue level (West et al., 
2014; Gilliam et al., 2011; Van Norren et al., 2009; Carvalho et al., 2009; Chen et al., 2007). One 
study suggests that 12 weeks of chemotherapy is comparable to an entire decade of cardio-
respiratory aging (Lakoski et al., 2012). However, several exercise interventions have 
successfully reversed the deconditioning process attributed by anti-cancer treatments, validating 
the important role of exercise in cancer rehabilitation.  
In general, previous findings demonstrate better functionality, symptom management, 
and HRQOL with exercise intervention (Courneya et al., 2007; Segal et al., 2009, Mishra et al 
2012; Burke et al., 2013; Cheville et al., 2013; Furmaniak et al., 2016; Brunet et al., 2017; Hsieh 
et al., 2008). Despite findings that exercise programs offer significant benefits to advanced 
cancer patients, professional kinesiologist consultations are not yet offered to patients as part of 
standard care services. Moreover, exercise guidelines for advanced cancer populations are still 
very unspecific and exercise prescription can be challenging, due to a multitude of factors that 
may influence the degree of physiological and functional decline from patient to patient. 
Currently, ACSM guidelines for exercise prescription in cancer population are loosely defined, 
and justly declare that “appropriate FITT recommendations will vary across cancer experience 
and requires individualization of Ex Rx” and, that “exercise tolerance may be highly variable 
during active treatment” (ACSM, 2013).  
One important factor that may influence how a patient will receive, and benefit from, 
exercise prescription is the presence and degree of cancer cachexia (ACSM, 2013). Cancer 
cachexia is associated with up to 75% loss of muscle mass in refractory cases (Preston et al., 
1987) and is described as a “complex metabolic syndrome associated with underlying illness” 
(Evans et al., 2008). To date, studies have shown that muscular strength and exercise capacity 





2010), suggesting that cachectic patients might respond to exercise differently, that they are more 
deconditioned, and that they might have different needs compared to other cancer patients 
(Hardee et al., 2017). However, current publications concerning exercise intervention fail to 
screen for cancer cachexia, and more research is required to evaluate the needs, tolerance and 
response to exercise for advanced cancer patients with versus without cancer cachexia.  
In this study, only patients, without cachexia, receiving supportive care were eligible to 
participate. The primary aim of this study is to examine pre-post interventional changes in 
function, strength, body composition, energy expenditure, and HRQOL. Our primary outcome 
measure for functional performance was the 6-minute-walk test, which is a validated measure for 
functional capacity in the cancer patient population. Secondary outcome measures included the 
Short Physical Performance Battery (SPPB) to further assess lower body functionality (balance, 
gait & sit-to-stand). Improvement in dynamic upper (bicep curl) and lower body strength was 
assessed using Theraband™ resistance bands. Isometric strength was assessed by handgrip 
dynamometry. In addition to traditional functional tests, body composition was assessed using 
DXA, and accelerometers were used to assess energy expenditure and step-count before and after 
exercise intervention. Lastly, the Edmonton Symptom Assessment System (ESAS) questionnaire 
to assess HRQOL, and the abridged Patient-Generated Subjective Global Assessment (aPG-
SGA) to also assess nutritional components. The secondary aim of the study is to assess 
feasibility of a 4-week, unsupervised, exercise program in stage 3 and 4 cancer patients without 
cachexia. Feasibility was evaluated based on: i) recruitment rate, ii) retention rates, iii) test 
performance, iv) exercise program tolerability and v) adherence. We hypothesized that patients 
would see improvements in functional scores, overall body strength, and energy expenditure 
when comparing pre-intervention assessments to post-intervention assessments. 
 
Methods 
This study was approved by the McGill University Health Centre Research Ethics Board 
(MUHC-REB), and they were responsible for monitoring this study.  Recruiment and data 
collection took place through the Cancer Rehabilitation Program of the McGill University Health 
Centre (MUHC).  
Recruitment took place on clinic days (every Wednesday and Friday) between March 2018 to 




eligible candidates and posted in clinic. All patients who fulfilled the following criteria were 
invited to participate in the study: Patients with stage 3 or 4 cancers who are receiving CRT or 
other comparable anti-cancer treatments and who are not cachectic according to the criteria 
defined in Appendix C (Vigano et al., 2016). The study also required that patients be able to 
ambulate without wheelchair or motorized chair. Patients expecting to receive surgery within the 
next 6 weeks or, expecting to finish their anti-cancer treatments in the next 4 weeks, were 
excluded. Contraindications for starting exercise defined by ACSM such as, experiencing fever, 
extreme fatigue, significant anemia or ataxia were not eligible. All recruited patients received 
clearance to engage in exercise by a physician and signed the MUHC-REB approved consent 
form prior to participating in the study. Participants of the study were allowed access to free 
parking. 
Study Design 
All study participants (N=21) received consultation with a kinesiologist and were 
prescribed exercise intervention for 4 weeks in addition to their standard care. The pre-post study 
design included 21 participants who were assigned the exercise program for 4 weeks (See Figure 
1). As seen in Figure 1, participants were assessed before and after the 4-week exercise program 
intervention. Each participant provided weekly progress reports via telephone to the 
kinesiologist.  
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A certified kinesiologist administered each assessment, which lasted no more than 1.5 
hours for each visit. All assessments took place at the MNUPAL cancer clinic. Measures for 
each assessment visit included weigh-ins, functional tests, a handgrip strength test and a DXA 
scan for tracking changes in body composition. As indicated in Figure 1, participants were 
contacted through telephone weekly, to discuss their exercise program progress and/or concerns. 
This way, if the exercise program was becoming too difficult or too easy, the kinesiologist would 
recommend program modifications or progressions. Moreover, another icon in Figure 1, 
demonstrates times during which participants were asked to wear an armband to track their 
activity. Participants were asked to wear SenseWear Pro® activity monitors for 3 consecutive 
days prior to the intervention, and 3 days prior to the end of the intervention. The activity 
monitors were useful to track changes in daily energy expenditures in calories and METS, as 
well as step-count. The 3-day wear time meant that participants wore the armbands when they 
woke up in the morning and removed it before bedtime, every day, for 3 days. Participants were 
also asked to complete aPG-SGA and ESAS questionnaires during both assessments in order to 
assess HRQOL and symptom profiles. An expectation questionnaire was also administered in 
post-intervention assessment and an exit survey was administered during the final assessment. 
 
Exercise Intervention 
As mentioned previously, patients were seen by a trained kinesiologist and prescribed an 
unsupervised, 4-week long, at home exercise program. During the first patient visit, after 
baseline assessment was completed, the kinesiologist took the time to thoroughly explain and 
demonstrate each component and exercise included in the exercise program. Participants were 
asked to repeat the demonstration to ensure they understood correct form. The exercise program 
itself included aerobic, resistance, balance and flexibility components. An instruction manual of 
the exercise program was handed to each participant. The manual included detailed written 
instruction for each exercise and included images of start point and end point in correct form. We 
asked that participants to perform the given program at least 3 times per week, totalling 12 
sessions over the 4-weeks. Participants were informed that each session should last 
approximately 40-45 minutes and that activity may be continuous or non-continuous. In other 
words, the patient could split up components of the program throughout the day to avoid 





walking per session, and participants were encouraged to do more if they felt capable. The 
resistance exercises mainly included seated, closed-kinetic chain exercises for upper and lower 
body using Therabands™.   Resistance training   using   Therabands™ has   been   effective   in   
similar   home-based   exercise programs for older adults and is recognized as a safe method to 
improve strength and functional ability in older adults and clinical populations (Zion et al., 
2003).  A total of 5 strengthening exercises for major muscle groups were prescribed, and 
participants were told to begin with 2 to 3 sets of 6 repetitions per exercise. The following 5 
exercises were included: sit-to-stand, seated chest press, seated row, calf raises and seated bicep 
curls.  Most resistance exercises could be done in the seated position using resistance bands 
(Therabands™) and the kinesiologist demonstrated proper form, always enforcing exhale on 
exertion, and, most importantly, a neutral spine position, for each exercise.  Resistance exercises 
were expected to take participants ~15 minutes to complete, with short breaks between each 
exercise. The resistance bands were chosen according to the patient’s capabilities shown during 
their 1st assessment. Participants were advised to begin the program with either a yellow, red or 
green Therabands™ and were provided with at least 2 extra bands for modification or 
progression purposes. To determine starting resistance, participants were asked to complete 1 set 
of 6 repetitions starting with the lightest resistance. At the end of the set, participants were asked 
if they felt any difficulty completing the set. If so, we recommended beginning with the lightest 
resistance; otherwise, after a 5 minute rest period, we asked the participant to repeat the set using 
the next resistance (and so on) until participant felt the resistance provided moderate exertion. 
This test was repeated each of the 3 exercises requiring the use of a Therabands™. For the 
balance component, the program included 3 balance positions and we asked that patients practice 
holding for 15 seconds on each side. These included the feet positioned together; one foot half 
way in front of the other (semi tandem); and the heel to toe stance (tandem).  A list of 4 stretches 
was also prescribed for the flexibility component (quadricep, chest/bicep, hamstring and back 
stretch) and participants were to perform them after their walk as a cool-down component. For 
patients with bone metastasis or spinal lesions, extra precaution called for minor changes in the 
program to ensure safety (e.g. removing back and hamstring stretches for patients with 
substantial spinal lesions). To ensure safety, participants were warned to immediately stop 






In addition to the program instruction manual, participants were also given a logbook, 
where they were asked to log details of each exercise performed throughout the 4 weeks. 
Participants’ adherence to the exercise program was rated based on the work recorded in their 




Outcome measures were selected based on reliability and validity of tests in cancer 




 The 6-minute walk test (6MWT) is used to measure functional walking capacity. The 
6MWT evaluates the ability of an individual to maintain a moderate level of PA over a time 
period reflective of the activities of daily living (Gillis et al., 2014). Subjects were asked to walk 
back and forth along a 15-meter stretch delimited by an orange cone at each end.  Before the start 
of the test, the assessor instructed participants to cover the greatest distance possible during the 
test.  Patients were allowed to rest during the test if needed, but this rest time is included in the 6 
minutes. Each minute, the assessor gave out a standardized motivational message to the 
participant, as per the American Thoracic Society guidelines.  Post administration of the 6MWT, 
the Borg Rating of Perceived Exertion was used for patients to identify the intensity level of the 
activity. The total distance covered was recorded by multiplying the total number of laps by 15 
meters, then adding the distance covered in the final lap. The 6-minute walk test is valid and 
reliable in cancer patients, and thus is recommended for use in this patient population (Schmidt 
et al., 2013).  A change in 6-minute walk test distance that falls within a range of at least 19 to 20 
m was considered the minimal clinically meaningful difference (Antonescu et al., 2014; 
Bousquet-Dion et al., 2018; Minnella et al., 2017).  To avoid inter-rater variability, the same 









To further assess lower body functionality, we used the 3 tests that comprise the Short Physical 
Performance Battery (SPPB). The SPPB was developed to test functionality in seniors; a 
population in which chronic disease is more prominent and functionality is sometimes 
compromised (Fisher et al., 2009). This battery is often used in hospitalized older adults, 
rehabilitation settings, and has been used to assess cancer patients (Fisher et al., 2009). It is 
often referred to as a ‘frailty index’ and is an important predictor of all-cause mortality in cancer 
patients (Pavasini et al., 2016; Guralnik et al., 1994). The SPPB evaluates balance, gait, lower 
body strength, and endurance by examining ability to stand with the feet together in the side-by-
side, semi-tandem, and tandem positions, time to walk 4 meters, and time to rise from a chair 
return to the seated position 5 times (Guralnik et al., 1994). Each of the 3 tests is timed and 
scored out of 4 points for a total of 12 points for optimal function. 
Handgrip strength was measured using the Jamar hydraulic hand dynamometer (Sammons 
Preston, Bolingbrook, IL). This test measures the maximum isometric strength of the hand and 
forearm muscles and is an indicator of general muscle strength (Hamilton et al., 1992).  Each 
participant's grip strength was measured twice on both hands and rounded to the nearest 
kilogram.  The handle was adjusted to the hand by ensuring the proximal interphalangeal joint of 
the middle finger was at 90 degrees. For handgrip strength assessment, subjects were seated, feet 
flat on the ground, both knees and test arm bent at a 90-degree angle. The assessor lightly held 
the base and the readout dial of the dynamometer, and asked the participant to exhale as they 
squeeze the handle.  During the test, participants were given the instruction to “squeeze as hard 
as you can, ...harder, ...and relax”.  The average score and peak score were compared to 
normative data. 
Body composition was measured via dual-energy x-ray absorptiometry (DXA; Lunar Prodigy 
AdvanceTM, GE Healthcare, Madison, WI). The DXA scan is a reference standard for assessing 
body composition (Buckinx et al., 2018) and a publication by researchers of MNUPAL has 
previously validated the use of DXA in advanced cancer patients (Trutschnigg et al., 2008). The 
GE Healthcare Lunar Prodigy machine was calibrated each day before any patient measurement.  
Participants were asked to remove any metals and sit with both legs centered on the midline of 
the scanning bed.  Once they laid down supine, their hands were placed in a neutral position with 





rolled up towel, and held in place with a Velcro strap.  For female participants, a Velcro strap 
was placed around the chest for extra support.  The approximate time for the total body scan is 
10 minutes.  The test printout indicates the amount in kilogram of lean body mass, fat mass, arm 
lean mass, leg lean mass and the percentage of body fat. Though all these values were recorded, 
appendicular skeletal mass is likely the most meaningful value for observing changes in muscle 
mass for the purposes of this study. This is because appendicular skeletal muscle index (ASMI) 
represents the main portion of muscles involved in PA and ambulation. To calculate ASMI, total 
arm and leg lean mass were added together and divided by the subject’s height in meters squared 
to obtain the appendicular skeletal muscle index.  
Feasibility measures included: patient recruitment, retention, and adherence to the protocol. 
Participants’ adherence to the exercise program was rated based on the work recorded in their 
logbooks (score/ of 12 complete sessions). 
The Edmonton Symptom Assessment System (ESAS) is a validated questionnaire (Bruer et al., 
1991) used at the MUHC to assist in the assessment of pain, tiredness, nausea, depression, 
anxiety, drowsiness, appetite, well-being, and shortness of breath. Each symptom is rated from 0 
to 10 on a numerical scale based on severity, with 0 indicating that the symptom is absent and 10 
that it is the worst possible severity. The total possible score is 100 and the higher the score, the 
worse overall HRQOL.  
Physical activity/metabolic expenditure during activity was monitored using SenseWear® Pro III 
Armband Monitors (BodyMedia Inc., Pittsburgh, PA). These activity monitors have been 
previously validated to measure daily energy expenditure in older adults (Mackay et al., 2011). 
These multisensor armbands incorporate a biaxial accelerometer that records steps per day, and 
physiological indicators of energy expenditure. These activity monitors have been used and 
validated in clinical populations, due to their valid and reproducible estimate of energy 
expenditure during walking at a slow to moderate pace (Patel et al., 2007), and a high correlation 
between steps per day and movement counts (Watz et al., 2008; Malavolti et al., 2007). 
Participants were asked to wear armbands for 3 consecutive days prior to each assessment.  
Nutritional status was assessed to help determine presence and degree of cachexia (Vigano et al. 
2016). The Abridged Patient-Generated Subjective Global Assessment (aPG-SGA) is a validated 
questionnaire used to assess the nutritional and functional status of cancer patients. The scoring 





intervention. The aPG-SGA may also be useful in monitoring short-term changes in nutritional 
status. A score ≥9 indicates a critical need for nutritional intervention (Ottery, 2004).  
Patient expectation questionnaire: a patient-subjective survey that was developed by the 
kinesiologist and used to assess exercise program expectations and personal goals before the 
intervention. See Appendix G. 
Patient satisfaction questionnaire: a patient-subjective survey that was developed by the 
kinesiologist and used to assess tolerance, adhesion, functional perception, enjoyment and 
overall satisfaction with the exercise intervention. See Appendix H. 
 
Statistical analysis  
 Outcome measures in this study called for quantitative analysis. Our null hypothesis 
posited that the mean 6-minute walk test performance in the pre-intervention assessment would 
be the same as that of the post intervention assessment.  Analysis included data collected from all 
21 patients with exception of one missing body composition scan. Generally, in larger studies, 
power is set to 0.8, meaning that the study has an 80% chance of ending up with a p-value of less 
than 5% in a statistical test with a difference that is unlikely due to chance. The calculated 
sample size required per group, for an ⍺ (two-sided) set to 0.05 and power set to 0.8, would have 
had to be in the proximity of 100 participants according to a Table by Hulley et al. 2013.  As 
such, our small sample size is only suitable for evaluating feasibility or as preliminary data to a 
future, larger trial with greater sample size and sufficient power. Analyses were performed using 
NCSS Statistical Software, version 11 (329 North 1000 East, Kaysville, UT). Pre-post 




  All details are presented in the CONSORT diagram in Figure 2.  According to numbers 
presented in CONSORT diagram below, retention rate is equivalent to 75% (21/28 = 0.75), 
calculated drop out rate is equivalent to 25% (7/28=0.25), and recruitment rate is equivalent to 





































Assessed for eligibility (n= 96) 
Excluded  (n=68) 
♦   Not meeting inclusion criteria (n= 54) 
 -Not receiving supportive anti-cancer 
treatments or ending anti-cancer treatments 
soon (n=23) 
-Are pre-cachectic, cachectic or moving to 
palliative care clinic (n=12) 
 -Are scheduled for surgery soon (n=3) 
 -Exercise is contraindicated (n=4) 
♦   Declined to participate (n=12) 
 -Already participating in other exercise 
program or feel that they are getting enough 
physical activity  (n=6) 
 -Live too far, don’t have enough time, or will be 
traveling for long period of time (n=6) 
♦   Other reasons (n=2 ) 
-Did not show up to appointments or return 
phone calls 
Lost to follow-up (n=5) 
♦ Completed intervention (n=21) 
♦ Discontinued intervention (n=5) 
       -Dropped out (n=5) 
Allocated to intervention (n= 28) 
♦ Received intervention (n= 26) 
♦ Did not receive allocated intervention  
-Withdrew at baseline or before commencing 
exercise intervention  (n=2) 
 
Analysed  (n=21) 










Demographic and Clinical Characteristics 
Participant demographic and clinical characteristics were also collected at baseline. 
Results are summarized in Table 1. Calculated mean age was 59 years (SD±14.35)  with the 
youngest participant aged 25 years and the eldest aged 86 years. Women held a small majority, 
representing 60% of the intervention group. Though the study included a wide range of primary 
cancer sites, 3 major cancers including, colorectal, lung, and breast represented more than half 
the group (n=12 of N=21). Most patients (n=13) had stage 4 cancer and a great majority of 
participants (n=17) were receiving ongoing chemotherapy treatments throughout their study 
involvement. However, it may be meaningful to note that all patients received chemotherapy as a 
treatment at some point, whether it was before or during their study involvement. During the 
study, 4 of the 17 patients on chemotherapy were combining treatments with hormone or 
immunotherapy. Equally noteworthy, is that 15 of the 21 participants had previously received 
surgery, and that 6 patients had previously received radiation therapies, though none were 
ongoing radiation treatment during the intervention. All patients were required to ambulate 
independently to be eligible for the study, but assistive devices were permitted and 2 patients 
using canes took part in the study. Remarkably, one amputee also completed the exercise 
intervention.  Cases that demanded extra caution and carefulness in exercise progression 


















Table 1: Patient (n=21) Demographics and Clinical Characteristics  
 
Age (years)  59.29 ±14.35 










































Stage: n (%) 
III 
IV 































Exercise Precautions: n (%) 









Axillary Web Syndrome (Cording) 1 (4.76) 




4.81 ± 1.86 
6.05 ± 2.18 
1Numbers in brackets denote percentages. 
2 Participants were asked to rate their perceived fitness levels from 1 to 10 in written baseline questionnaire. A score 
of 10 signified most active or most deconditionned score. See full questionnaire in Appendix G. 
 
Anthropometrics and Body Composition 
Anthropometrics and body composition data were recorded pre and post exercise 
program and paired t-tests yielded results summarized in Table 2 (see below). Due to one 
incomplete DXA scan in post-intervention group, analysis compared pre-inervention group of 
N=21 to post-intervention group of N=20 for all body composition analyses. Statistical 
significance was set at p ≤ 0.05. Average baseline height and weight were 70.93 kg (±18.91) and 
1.67 m (±0.09) respectively. Post-intervention weight was slightly increased (p = 0.063). Fat 
mass and body fat percentage were generally maintained.  Bone mineral density, lean leg and 
arm mass, appendicular skeletal mass index (ASMI) were generally maintained and showed no 
meaningful change over the 4-week program. At baseline, a total of 11 participants were 
classified as sarcopenic based on ASMI cuttofs defined by Baumgartner et al. (1998). One 
participant who was sarcopenic before exercise intervention was no longer sarcopenic in post-


















Table 2: Anthropometrics and changes in body composition after the 4-week intervention 





Weight (kg) 70.93 (±18.91) 71.36 (±18.73)   0.063* 
Height (m) 1.67 (±0.09) 
 
-   - 
2Body Mass Index (kg/m2) 25.3 (±6.6) 25.5 (±6.5)   0.074 
2Body Fat (%) 35 (±10.3) 
 
34.3 (±9.2)   0.957 
2Fat mass (kg) 24.6 (±12.7) 24.7 (±12.8)   0.617 
2Lean body mass (kg) 42.2 (±8.9) 43.5 (±8.9)   0.066* 
2Bone Mineral Content 
(kg) 
2.78 (±0.6) 2.80 (±0.62)   0.660 
2Lean arm mass (kg) 4.36 (±1.38) 4.34 (±1.28)   0.380 
2Lean leg mass (kg)  13.1 (±3.4) 13.6 (±3.3) 0.258 










   
- 
 
Numbers in brackets denote standard deviation of means (SD). P-values determined using paired T-test. 
1 Significance set to p ≤ 0.05.  
2 One incomplete DXA scan required analysis of n=20 for post-intervention group.  
3 Sarcopenia based on ASMI cut-offs <5.45 for women <7.26 for men (Baumgartner et al., 1998).  
*Denotes trending result. 
 
 
Functional Outcome Measures 
Most functional measures showed significant differences after the intervention (See 
Table 3 below). Handgrip strength (HGS) values improved over time with significant increases 
in mean score (p=0.003), peak score (p=0.004) and associated percentile rank (p=0.006). Short 
Physical Performance Battery (SPPB) results show significant improvement in repeated sit-to-
stand time (p=0.025) and associated point score (p<0.001), resulting in a significantly improved 
overall SPPB point score (p<0.001). Balance and 4m-Gait-Speed Test (GST) scores did not 







Primary Outcome Measure 
As seen in Table 3, statistically and clinically significant changes were observed in the 6-
minute walk test distance (6MWTD) (p<0.001).  Mean group change in 6MWT distance was 
+44.2± 38.0m (𝑥 � ±  SD) between pre and post-intervention scores. Refer to Table 4 for number 
and percentage of participants having achieved clinically significant changes in 6MWTD. 
Ratings of perceived exertion using the Borg scale were determined to be “moderate” and were 
similar pre and post intervention. Both participants with canes chose to perform their 6MWTs 
without the use of their assistive device. 
 
Table 3: Functional outcome measures over time 
Outcome measures Pre-Intervention 
(N=21) 
Post-Intervention (N=21) P-value1 
















Short Physical Performance Battery 
(time) 
4-Meter Gait Speed 













2Short Physical Performance Battery 
(points)  
Balance 
4-Meter Gait Speed 




















 6-Minute Walk Test (m) 







Numbers in brackets denote standard deviation of means (SD). P-values determined using paired T-test. 
1 Significance set to p ≤ 0.05. 
2 Each of the 3 tests included in this battery, were score in points according to results tables provided in SPPB 
testing guidelines. Each of the tests were scored on a total of 4 points, for a grand total score over 12 points. 
3 Borg scale was used to measure ratings of perceived exersion after 6MWT. 
* Denotes statistically significant result. 










Table 4: Number of participants achieving clinically significant change in 6MWT distance 
Clinically significant change in 6MWT distance 
1Group mean difference in 6MWTD (𝑥 � ±  SD) +44.2± 38.0m 
Number and percentage of participants achieving: 
 
2MCMD (>20 m difference in 6MWTD) 
Improvement ≤20 m difference in 6MWTD 






16MWTD = 6-Minute Walk Test Distance 
2MCMD =Minimal Clinically Meaningful Difference for 6MWT as defined by Antonescu et al. 2014; 
Bousquet-Dion et al., 2018; Minnella et al., 2017. 
 
Activity Monitor Data 
Energy expenditures were also recorded 3 days prior to the start and before the end of the 
intervention. Results generated by the SenseWear Pro® activity monitors include daily stepcount 
and energy expenditures in both calories and metabolic equivalents (METs). Activity monitor 
data is summarized in Table 5 below. The monitors are programmed to identify sedentary, 
moderate and vigourous activity based on programmed MET cut-offs. For the purpose of this 
study, any energy expenditure (EE) <3 METS was considered sedentary behaviour; EE ≥3 METs 
and ≤ 6 METs was considered “moderate” PA; and EE >6 METs and < 9 METs was considered 
vigorous PA. As seen in Table 5, most activity monitor results were highly significant and 
reflect increased average stepcount (p < 0.001) and EE (p < 0.001) post-intervention. Notably, 
most increases in EE are due to increases in moderate PA rather than vigorous PA, but both 
moderate and vigorous activities show significant increases after the exercise program (p < 0.001 
and p = 0.039 respectively). Lastly, sedentary behaviour showed an overall decrease though it 












Table 5: Activity Monitor Data over Time  

















Number of Steps 
Daily Average 










3Daily Average “Active” EE (kcal) 291.47 (±306.65) 461.98 (±367.1) <0.001* 




















Daily Average Sedentary Behaviour 
Duration (hrs) 
11.20 (±2.55) 10.59 (±2.35) 0.166 
Numbers in brackets denote standard deviation of means (SD). P-values determined using paired t-test.  
1 Significance set to p ≤ 0.05. 
2 EE=Energy Expenditure; METs= Metabolic Equivalent or kcal/kg/hr; PA=Physical Activity; kcal = kilocalories; 
hrs = hours 
3 For the purpose of this study, PA or “Active” Energy Expenditure represents an EE ≥3METs. 
4 For the purpose of this study “moderate” PA represents an EE ≥3 METs and ≤ 6 METs; “vigorous” PA represents 
an EE >6 METs and <9 METs.  
* Denotes statistically significant result. 
 
Symptom and HRQOL assessment questionnaires 
Abridged PG-SGA and ESAS questionnaires were used to assess symptoms and HRQOL 
before and after the intervention. Total scores for each questionnaire were analyzed but did not 
bear statistically significant results (See Appendices D and E to view full questionnaires). Note 
that, from the symptoms rated in the ESAS questionnaire, pain was generally rated lower post-
intervention and demonstrated a statistical trend (p = 0.06). Questionnaire total score results, as 












Table 6: Pre-Post Intervention Subjective Symptom Assessment Questionnaires 
 





















































































Numbers in brackets denote standard deviation of means (SD). P-values determined using paired T-test.  
aPG-SGA = Abridged-Scored Patient-Generated Subjective Global Assessment (See Appendix E) ; ESAS = 
Edmonton Symptom Assessment System (See Appendix D). Lower scores denote better health related quality 
of life in both questionnaires. SOB=Shortness of breath 
1 Significance set to p ≤ 0.05. 
2 Refer to Appendix E to view each aPG-SGA questionnaire section and how each is scored. 




Exit Survey Scores, Logbook Adherence  
After the exercise intervention was completed, an exit survey (see Appendix H) was used 
to assess patient satisfaction with the exercise program. The exit survey required patients to score 
tolerance, motivation, function and enjoyment of the exercise program on a scale of 1 (lowest) to 
5 (highest). An average score out of 5 was calculated for each factor and results are presented in 
the first 4 rows of Table 7. Reasons for missing training sessions were also quantified and the 
most frequent answer proved to be fatigue with 13 participants (~62%) reporting this reason for 
missed sessions. Pain and other symptoms were also listed as reasons for missing exercise 





The exercise data obtained from patient logbooks were also analyzed in order to assess 
adherence to the exercise prescription. Because the exercise program called for a total of 12 
sessions (3 sessions/week for 4 weeks), completion of each component of the program (cardio, 
resistance, balance and flexibility) was tallied out of 12, in order to obtain a total score out of 48 
for overall adherence. On average, the patients completed approximately 85% of the exercise 
sessions. 
 
Table 7: Post-Intervention Exit Survey Scores and Logbook Adherence 
Outcome measures  
Tolerance (x/5) 4.09 ±0.941 
Motivation (x/5) 3.74 ±0.921 
Improved Function (x/5) 3.64 ±0.941 
Enjoyment (x/5)  4.40 ±0.661 
Possible Reasons for Missing Training Sessions: n (%) 
Fatigue  
Pain or other symptoms 














Total Adherence Score (x/48) 
 
11.1 ±1.61 (92.5) 
10.14 ±1.96 (84.5) 
9.19 ±3.63 (76.6) 
10.24 ±3.03 (85.3) 
40.67 ±6.8 (84.7) 
Numbers in brackets denote percentages. 
1 Participants were asked to rate their perceived tolerance, motivation, functional change and program enjoyment in 
a post intervention exit survey. Scales were from 1 to 5 (best outcome). See full questionnaire in Appendix H. 
 
Theraband Use and Progression 
Lastly, we quantified the use of each Therabands™ based on the frequency each band 
color appeared in participant logbook records for each exercise. Out of the 5 resistance exercises 
prescribed, 3 exercises required the use of Therabands™ (seated chest press, row and bicep curl). 




weight rather than Therabands™ (Sit-to-Stand & calf raises). Different colors represent a 
different resistance and are listed from the least to the most resistance in Figures 3, 4 and 5 
(yellow, red, green, and blue). In terms of most commonly used resistance bands, the majority of 
participants reported using the red band (90.5%, n=19) at least once, at some point throughout 
the program. The second most frequently used color was the green band, and was used by 76% 
(n=16) of participants, at least once, at some point during the study.  Because each color-band 
corresponds to a resistance in kilograms at 100% elongation, we were able to quantify the 
group’s total resistance for every exercise, every week, and view their overall progression.  To 
view color bands’ associated resistance in kilograms at 100% elongation see Appendix I or refer 
to legend of Figures 3, 4 and 5. Represented in Figures 3, 4 and 5 below, you will see the 
number of participants that reported using each color band, every week. In addition, under each 
week is the total calculated resistance for the group (in kg) and the corresponding collective 
percent increase in resistance from the previous week. Lastly, the overall percent progression is 
bolded under each figure and ranged between 21-29% increase between weeks 1 and 4. Paired t-
tests between resistances used in week 1 and week 4, show that strength progression for the chest 
press (1.64 ±0.29 vs. 1.98 ±0.32 kgs; p<0.001), seated row (1.66 ±0.24 vs. 2.06 ±0.32 kgs; 
p<0.001), and bicep curl (1.55 ±0.23 vs. 2.0 ±0.28 kgs; p<0.001) was significantly increased over 
time.ooo 


















Recruitment rate, Dropout rates & Adherence 
Based on figures from the CONSORT diagram (Figure 2), we reported a dropout rate of 
25% and a recruitment rate of 29%. These figures are comparable to findings by Oldervoll et al. 
(2004), who reviewed results of 12 similar exercise interventions in cancer populations. This 
review reported varying drop-out rates up to 34% and average recruitment rate of 43% 
(Oldervoll et al., 2004). Though our study reports a smaller recruitment rate, this is likely owed 
to more specific inclusion criteria in order to screen for cachexia. In addition, our study focused 
on more advanced cases than those reviewed by Oldervoll (2004), many of which were non-
curative, and thus, more difficult to recruit. For these reasons, we do not expect to generalize this 
study’s findings to all cancer patients, but to better understand the impact of the current exercise 
prescription in a more specific group (advanced supportive care cancer patients without 
cachexia). Oldervoll et al. (2004) also reports an average adherence rate to exercise prescription 
of 72%, for which, our study reports 85% based on participant logbooks (See Table 7). One 
possible reason for the study’s successful adherence rate may be due to our weekly phone check-
ins which encouraged adherence to the exercise program. A high adherence rate may also be 
attributed to our study’s relatively short (4 week) intervention period, as compared to studies 
reviewed by Oldervoll et al (2004), which were generally longer than 6 weeks. Based on our 
results, a four week exercise program is sufficiently long to demonstrate significant changes in 
6MWT, strength, and energy expenditure and is more amenable to retaining advanced cancer 
patients than longer interventions. 
 
Demographics and Clinical Characteristics 
In terms of subject demographics, we included different ages, and mixed cancer 
diagnoses, which allowed for better recruitment rate. Leading cancers were well represented in 
our sample given that 3 major cancers including, colorectal (n=4), lung (n=4), and breast (n=4) 
represented more than half the group (n=12). Over 80% of participants were receiving 
chemotherapy during their study involvement, but all participants received chemotherapy at 
some point in their cancer journey. The few patients who were not receiving chemotherapy 
during the study intervention remained on hormonal or immune therapies. Furthermore, over 





participants received treatments which, they felt, contributed to the demise of their normal 
functioning. As indicated in Table 1, most patients reported low self-perceived Fitness Scores in 
baseline questionnaire, rating their “level of de-conditioning” (𝑥 ± SD; 6.05 ± 2.18) higher than 
their “level of activity” (𝑥 ± SD; 4.81 ± 1.86) on scales of 1 (lowest) to 10 (highest).  
 
Body composition 
Concerning changes in body composition measures, DXA scans revealed little significant 
change over the 4-week exercise intervention. This is likely due to a relatively short intervention 
period, not allowing enough time to quantify much physiological change. However, despite little 
statistically significant change in body composition, one may note that some group means are 
trending in promising directions, especially in terms of lean mass (p=0.0066), which was 
generally increased post-intervention (𝑥 ± SD; 0.74 ± 1.6 kg). Increase in weight was also 
trending (p=0.063), with no significant change in body fat percentage or fat mass, indicating that 
weight gain was more possibly due to increases in lean mass. Most importantly, participants 
were generally able to maintain their body composition over the 4-week exercise program, 
despite the cumulative fatigue, and effects of treatments, that may have otherwise solicited 
deterioration (Freedman et al., 2004).  
 
Functional Testing 
Though body composition statistics did not indicate much change, functional testing 
revealed more significant results. Notably, results of the primary outcome measure showed both 
statistically and clinically significant changes in 6MWTD.  Clinically significant change in 
6MWTD was attained by those achieving a minimal clinically meaningful difference (MCMD) 
value >20m as defined and observed by others (Antonescu et al., 2014; Bousquet-Dion et al., 
2018; Minnella et al., 2017). Consequently, results indicate that 81% of participants (n=17) 
showed clinically significant improvement (>20 m) in their walking capacity post-intervention, 
with but one participant showing regression.  
Total functional score provided by SPPB also showed statistically significant 
improvement post intervention (p<0.001). Given that the sit-to-stand exercise was performed by 
participants over the 4 weeks, significant change in this test was unsurprising. In fact, it is 





repeated sit-to-stand test performance (p<0.001). Both 4-m gait speed test and balance test did 
not demonstrate meaningful change over time (p=1 and p=0.643 respectively). Pre-post balance 
scores did not change at all, as most participants scored 100% of their points in their first visit, 
reaching a performance ceiling even before commencing exercise intervention. As such, the 
balance test was not considered sufficiently sensitive to change, and poses an insensitive-
measure bias in this population.  An alternative, balance test to use in this patient population is 
the single leg stance test, which is more difficult and sensitive to change.  
Although improvements in functional performance are not necessarily reflected by 
important changes in our reported body composition measures, improved functional performance 
can be attributed to many other factors. For instance, cardiorespiratory changes, like increased 
VO2peak, can increase walking capacity and translate to improvements in shuttle walk tests (Singh 
et al., 1994; Quist et al., 2012). Alternatively, increased motor unit recruitment, can explain early 
improvements in performance even without muscle hypertrophy (Moritani and deVries, 1979). 
In turn, an improved symptom profile (e.g. pain symptoms), can motivate participant to perform 
better (Reis et al., 2018). 
 
Activity Monitor Data 
Very few advanced cancer studies to date have reported using accelerometers, even 
though they are best suited to provide objective measures of energy expenditures (Broderick et 
al., 2013). Instead, most studies rely on self-report measures (Dahele et al., 2007). Broderick et 
al. (2013) suggest that, accelerometry may be the best measure of PA in cancer-based studies, 
because of high accuracy and minimal wearer burden. In current cancer publications, some small 
studies have reported the use of accelerometers (Freeny et al., 2011; Guinan et al., 2013; Walsh 
et al., 2010), and there are reports of increased use in recent, larger cancer-survivor studies 
(Lynch et al., 2007; Courneya et al., 2012). However, none of these studies examine pre-post 
exercise differences in energy expenditures and step counts for supportive care patients. 
In the present study, meaningful changes in energy expenditures imply that prescribed 
exercises promoted the adoption of more active behaviours. One may note that pre-intervention 
daily average energy expenditures (EE) and stepcounts were very low according to the American 
College of Sports Medicine (2014) that stated that energy expenditure under 3 METs is 





(2004), daily step-counts under 5000 steps are categorized as “sedentary or inactive lifestyles”. 
Thus, averages of daily EE of 1.53 METs and step-count of 3576 steps/day reflect a highly 
inactive and deconditioned group at baseline. In terms of kilocalories spent in PA, only 16% 
(291 calories/day) of the total 1775 kcals/day were expended actively (>3 METs), based on 
baseline data. According to Ainsworth et al.’s (2011) compendium of physical activities, for a 
person weighing ~73kg (160 lbs), 290 kcals could represent an hour of gardening or raking the 
lawn for example. In comparison, for the post-intervention value of 460 kcals expended in PA, 
Ainsworth et al.’s (2011) compendium of physical activities, describes activities like an hour of 
hiking or shovelling snow for a person of equal weight. On average, at the end of the 
intervention, participants expended 22% (462 calories/day) of their total EE (2142 kcals/day) in 
PA (>3 METs). In other words, participants expended significantly more calories engaging in 
activities >3METs after the exercise intervention.  In terms of stepcount, the group showed a 
total average increase of 1367 (±910) steps (~38%) in end-intervention from baseline. Hence, 
results from accelerometers post-intervention, show a trending increase in EEs, step-count and 
PA. Regarding time spent in PA (>3METs), results indicate a total increase of 0.62 hrs (or +37 
mins) of PA per day when comparing pre vs. end-intervention PA duration. The increase in PA 
duration is largely attributed to increase in moderate activity, with a very small, but equally 
significant, increase in vigorous activity. To conclude, though increases in energy expenditure 
were sufficient to significantly reduce body weight or percent body fat over the 4 weeks, the 




We also compiled results from symptom management questionnaires aPG-SGA and 
ESAS and found there to be little change between pre-post intervention scores. In fact, total 
score for aPG-SGA was relatively maintained, implying that participants did not perceive 
considerable change in their symptom profile or HRQOL in the 4 weeks since baseline. 
Similarly, total ESAS score did not prove to be statistically significant, despite a more promising 
drop in overall score. Comparably, other short-term studies also found no remarkable change in 
HRQOL and symptom profiles (Dimeo et al., 2008; Adamsen et al., 2003). It may, however, be 





Therefore, it is possible that the perceived decrease in pain is owed to mechanical or 
neuromuscular improvement on account of the exercise intervention, similar to reports in other 
studies (Reis et al., 2018; Do et al., 2015). However, reduction in pain may also be due to other 
interventions on account of standard care (e.g. new drug prescription), and, thus, the study would 
necessitate a control group to better examine the direct effects of the exercise intervention. All in 
all, given that patients continued receiving anti-cancer treatments throughout their study 
involvement, it is reasonable to expect continuing symptoms and side-effects throughout the 
study, and it is important to recognize that patients did not feel like their condition deteriorated 
over the 4-week intervention. This observation is supported by the fact that HRQOL and 
symptom profiles were generally well maintained.  
In regards to results from the exit survey, we may conclude that the prescribed exercises 
were well tolerated by the majority of participants (𝑥 ± SD, 4.09 ± 0.94 on a scale from 1 to 5). 
Additionally, most participants claimed to enjoy their experience with the exercise program (𝑥 ± 
SD, 4.4 ± 0.66) and were usually motivated enough to complete the sessions (𝑥 ± SD, 3.74 ± 
0.92). The majority of participants also reported self-perceived improvements in function with an 
average score of 3.64 ± 1.86 (𝑥 ± SD) on a scale of 1 to 5, which agrees with improvements seen 
in our study’s functional outcome measures. With regards to possible reasons for missing 
exercise sessions, the most cited cause was “fatigue” (reported by n=13, 62%), followed by “pain 
or other symptoms” (reported by n=8, 38%). In other words, patients were more likely to miss an 
exercise session because of presenting symptoms, and not because the program was too difficult 
or due to a lack of time. Having said this, participants did not seem to miss too many exercise 
sessions, given that our total adherence rate was 85%. Upon a closer look at reports in logbooks, 
balance exercises were the most likely to be neglected (balance adherence = 76.6%), and cardio 
sessions were most rarely passed up (cardio adherence = 92.5%). 
 
Theraband Progression 
To date, very few cancer studies using Therabands™ (Gillis et al., 2014, Gillis et al., 
2016, Bui et al., 2019) will detail band progression in their results. Information regarding 
exercise progression is especially important in clinical populations such as advanced, supportive 
care cancers, because exercise prescription guidelines are either vague or lacking. We have 





results revealed that change in resistance from week 1 to 4 was statistically significant for each 
of the 3 exercises. There was a clear progression between each week, but the greatest 
progressions were between weeks 2 and 3. At this point in time, most participants had progressed 
from the color band they started with in week 1. The bicep curl exercise showed the greatest 
collective improvement because more participants started with lighter resistances (yellow or red), 
perhaps, given that it is a smaller muscle group. We also note that the most frequently used 
bands are red and green for this clinical population. Though similar short-term cancer studies 
also demonstrate improvements in strength (Adamsen et al, 2003, Quist et al., 2012), they did not 
measure body composition or changes in lean mass. Once more, despite insignificant change in 
our participant’s lean arm mass, early neuromuscular adaptations, such as improved motor unit 
recruitment, could be responsible for observed improvements in strength in the absence of 
hypertrophy (Moritani and deVries, 1979). 
   
Conclusion 
Our findings imply that 4-week, unsupervised, resistance and walking training program, 
is beneficial to, and well tolerated by, advanced cancer patients in supportive care. Comparisons 
between pre-post intervention outcome measures revealed promising improvements in functional 
performance, namely, clinical and statistical increase in walking capacity. Further, lower body 
strength showed significant improvements based on meaningful change in time required to 
perform 5 sit-to-stand repetitions. Similarly, upper body strength showed improvement based on 
Theraband™ progression analysis, as well as, significant increase in HGS results. Activity 
monitor data (collected with SenseWear Pro®) indicates significant increases in EEs at the end 
of the intervention, with more calories expended in PA than at baseline, even, after only 4-
weeks. Although change in EE was not sufficient to significantly alter body composition values 
in a 4-week time frame, a promising trend in increasing lean mass, combined with improved 
walking capacity and strength, could indicate the beginnings of more significant change in body 
composition, and more research is required to observe body composition, and PA patterns, 
perhaps, over a longer period of time and post-intervention. In addition, HRQOL and symptom 
profile were well maintained throughout the 4-week exercise programs, with no marked 
deterioration, despite continuing treatments. In fact, a trending decrease in pain was observed 





to the exercise intervention. Because of our study’s small sample size and limited resources, we 
must recognize some important limitations, which are highlighted in the following chapter. 
Fortunately, our study protocol showed optimistic feasibility based on positive recruitment rate, 
retention rates and adherence, all of which encourage the opportunity for a future randomized 
control trial. As such, the following chapter will also discuss potential future directions of this 
work. In sum, our study results encourage the combined use of Therabands™ and self paced-
walking as a safe, well-tolerated, and functionally impactful exercise prescription even after 4-
weeks time. In clinical terms, we conclude that 4-week prescriptions combining resistance and 
self-paced walking exercises may be used to increase walking capacity and energy expenditure, 
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Our study results support many benefits of exercise, despite its short 4-week time frame. 
Based on this study’s findings and similar findings in previous research, safe, light-to-moderate 
exercise intervention should be encouraged in advanced cancer patients at least 3 times/week. 
Further, because our study focused on patients who have not been afflicted by cancer cachexia, 
and, was well received, we can assume that the given prescription was a suitable starting point 
for this patient population.  In regards to future direction, it would be interesting to compare non-
cachectic patients to those afflicted by cancer cachexia, in terms of how differently they would 
respond to the given intervention. However, as mentioned previously, it is also important to 
recognize the limitations of the current study in order to optimise future research and larger scale 
randomized control trials (RCT). The following sections, will examine limitations and future 




Given that, the current study is a pilot study we do not expect to generalize the results of 
this small cohort. Based on the calculated effect size, a future RCT would require ~100 
participants per arm in order to sustain power of 80% (α = 0.8) (Hulley et al., 2013).  In addition, 
an RCT would call for a control group where participants are not receiving the prescribed 
exercise intervention. Because our analysis did not compare findings to a control group, it does 
not measure the effects of standard care against those of the exercise intervention.  
Our current study also helped us identify some technical limitations. In terms of the 
DXA, potential errors can occur through technical error or biological variation (Lohman et al., 
2000; Nana et al., 2015).  Technical errors would include variation induced by calibration or 
failure to calibrate, and variations in positioning or regional analysis of the participant (Toomey 
et al. 2017). Biological variation could occur by effects of food, fluid intake, and hydration status 
before measurement (Toomey et al., 2017). For instance, the DXA machine, used to assess body 
composition, does not recognize edema or fluid retention in patients, and, instead, will identify 
edematous tissues as lean mass.  Because lymphedema is a reality for a number of cancer 
patients, future studies should consider screening for lymphedema, to avoid possible 





composition, especially for patients receiving treatment, because significant water retention or 
dehydration can occur by adverse effect (Behar et al., 2003; Sarhill et al., 2001). In the current 
study, one participant was asked to return for final weigh-in and DXA scan, because she was 
visibly swollen after receiving treatment, and, by the next day, her water retention had visibly 
decreased. In the present study, fluid hydration status was not controlled. Though, it may be 
difficult to control for this, reducing this bias would involve estimating similar assessment times 
in relation to specific time points in treatment cycles.  
Another limitation of the study that could help explain little change in body composition 
is that no nutritional component was involved in the intervention. A number of multimodal 
studies suggest that combining nutrition and exercise can better help preserve muscle mass, but 
more research is required to support this claim (Gillis et al, 2016; Gillis et al. 2014, Bui, 2019). 
In regards to group demographic, our cohort included a variety of different baseline 
capacities, a wide range of ages, and different cancer types. We also had slightly more women 
than men participants, but sample size was too small to make sex comparisons, or comparisons 
between aforementioned demographic variables. Whilst we cannot ignore possibility of a 
heterogeneity bias, it seems the group was homogeneous enough to show collective 
improvements in function and active behaviour. In larger sample sizes, demographic and clinical 
comparisons can be made between groups, to control for variability of outcome measures.  Other 
sources of variability in advanced cancer populations could include patients with bone 
metastasis, axillary cording, and lymphedema, but more research is needed to examine this front. 
Naturally, each outcome measure also has its limitations. In terms of functional 
assessment tools, we noted that tandem balance tests had a really high success rate at baseline, 
and left little opportunity to assess improvement post-intervention. As such, we recommend the 
use of a test with a higher performance ceiling (e.g. single leg stance) in future works. In terms 
of our primary outcome measure, the 6MWT, we used the same long corridor for each 
assessment, to limit the number of turns and reduce variability. Because the same assessor (FP) 
performed pre-post outcome measures, we avoided inter-rater variability, but experimenter’s bias 
is possible.  Another possible source of variability in 6MWTD is the learning curve associated to 
the test. According to Spencer et al. (2018), to eliminate learning curve bias and increase 





In regard to activity monitors, there does not seem to be a clear consensus on the 
minimum wear time required for valid monitoring (Broderick et al., 2014). Masse et al. (2005) 
propose that a conservative estimate lies between 3 to 7 full 10 hour days, or days for which 60% 
of waking hours are represented.  According to Pitta et al. (2005) minimum requirements to 
assess PA in daily life is 2 days. However, a cancer population study conducted by Maddocks et 
al. (2010), recommends up to 6-days of monitoring to best reflect habitual levels of activity. Our 
study examined activity monitor data from 3 days’ wear before and after exercise intervention, 
meeting the proposed “minimum” requirements. Participants were instructed to wear armbands 
when they woke up in the morning until bedtime, which covered at least 60% of waking hours. 
Lastly, it has been suggested that weekend days and weekdays need to be sampled (Gretebeck et 
al., 2005) since there’s a possibility of EE differences between weekdays and weekend days.  
Lastly, given that the intervention was unsupervised, we could not verify logbook records 
obtained by participants. Some might argue that, because of this, progression may have been 
limited, given the lack of trainer motivation and security, during training sessions. If resources 
permit it, supervision of at least one of three training sessions per week could further encourage 
progression and motivation.  To otherwise fulfill a sense of encouragement and security, it was 
important to include weekly phone check-ins with participants and remain accessible by phone to 




Though our study was limited by several factors, we find that it is sufficiently feasible to 
replicate, and develop into a larger-scale RCT. In practice, our results show that significant 
change in 6MTD, strength, and energy expenditures are achievable in a relatively short 4-week 
period. Given the functional impact and high adherence rate associated to this time frame, 4-
week exercise interventions are recommended to similar future works. Moreover, our study 
results encourage the combined use of Therabands™ and self paced-walking as a safe, well-
tolerated, and functionally impactful exercise prescription. Future interest would lie in 
comparing how pre-cachectic and cachectic groups respond to similar exercise interventions. 
Adding a nutritional component to future works could also shed light on the impact of combined 





previously, a RCT would require ~100 participants in each arm to confirm results are not 
experimental error. To conclude, much more research is required to optimize the specificity and 
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Appendix B – Cancer “TNM” Staging System 




















































weight rather than Therabands™ (Sit-to-Stand & calf raises). Different colors represent a 
different resistance and are listed from the least to the most resistance in Figures 3, 4 and 5 
(yellow, red, green, and blue). In terms of most commonly used resistance bands, the majority of 
participants reported using the red band (90.5%, n=19) at least once, at some point throughout 
the program. The second most frequently used color was the green band, and was used by 76% 
(n=16) of participants, at least once, at some point during the study.  Because each color-band 
corresponds to a resistance in kilograms at 100% elongation, we were able to quantify the 
group’s total resistance for every exercise, every week, and view their overall progression.  To 
view color bands’ associated resistance in kilograms at 100% elongation see Appendix I or refer 
to legend of Figures 3, 4 and 5. Represented in Figures 3, 4 and 5 below, you will see the 
number of participants that reported using each color band, every week. In addition, under each 
week is the total calculated resistance for the group (in kg) and the corresponding collective 
percent increase in resistance from the previous week. Lastly, the overall percent progression is 
bolded under each figure and ranged between 21-29% increase between weeks 1 and 4. Paired t-
tests between resistances used in week 1 and week 4, show that strength progression for the chest 
press (1.64 ±0.29 vs. 1.98 ±0.32 kgs; p<0.001), seated row (1.66 ±0.24 vs. 2.06 ±0.32 kgs; 
p<0.001), and bicep curl (1.55 ±0.23 vs. 2.0 ±0.28 kgs; p<0.001) was significantly increased over 
time.ooo 





























Appendix B – Cancer “TNM” Staging System 














































Appendix I – Theraband™ Color Progression Chart  
 
 
